Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655285 | 1.00 | CHEK2 (0.46) | CHEK2CXCR3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL9774872 | 0.92 | CXCR3 (0.49) | CHEK2CXCR3PTGDR2NPC1RAB9A | |
| SCHEMBL5247027 | 0.77 | CXCR3 (0.56) | CXCR3PTGDR2NPC1RAB9AMAPT | |
| SCHEMBL5243748 | 0.73 | CXCR3 (0.48) | CXCR3PTGDR2NPC1RAB9AKCNH2 | |
| Hydrochloric Acid SCHEMBL23359867 | 0.71 | CHEK2 (0.50) | CHEK2SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL29862670 | 0.71 | CHEK2 (0.50) | CHEK2SLC6A4SLC6A2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL23359866 | 0.71 | CHEK2 (0.50) | CHEK2SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL15066613 | 0.71 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3KCNH2BCHE | |
| SCHEMBL15066153 | 0.71 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3KCNH2BCHE | |
| SCHEMBL11330961 | 0.70 | MAPT (0.48) | NPC1RAB9AMAPTHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5010198-A | Intermediates for the synthesis of benzoxazol- and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-23 | — | — | US | claimed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2234999-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| CN-1014790-B | PROCESS FOR PREPARING NOVEL BENZOXAZOL-AND BENZOTHIAZOLAMINE DERIVATIVES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 1991-11-20 | — | — | CN | disclosed |
| US-5010198-A | Intermediates for the synthesis of benzoxazol- and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-23 | — | — | US | disclosed |
| EP-0184257-B1 | BENZOXAZOL- AND BENZOTHIAZOLAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-25 | — | — | EP | disclosed |
| US-4861785-A | Benzoxazol-and benzothiazolamine derivatives, useful as anti-anoxic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-08-29 | — | — | US | disclosed |
| CN-85108556-A | The preparation method of novel benzoxazol base and benzothiazolyl amino derivative and application thereof | — | 1986-07-30 | — | — | CN | disclosed |
| EP-0184257-A1 | Benzoxazol- and benzothiazolamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | CHEK2 4689/4885CXCR3 1077/4885SLC6A4 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.